Diabetes medications, devices and supplies are important for people with diabetes to effectively self-manage their disease, so that they can live a healthy life.

Across the country, the Canadian Diabetes Association advocates to governments for equitable and affordable access to these essential supports on behalf of people living with diabetes and their caregivers.

As part of our advocacy efforts, the Canadian Diabetes Association makes patient input/evidence submissions to federal and provincial drug review bodies including the Common Drug Review, BC PharmaCare and Ontario Drug Benefit (ODB) Program. The Common Drug Review reviews the drug and then a committee makes recommendations on what drugs should be covered (insured) by provincial/territorial drug plans (except Quebec). Provincial/territorial drug plans then review each manufacturer’s request to fund its drug and make funding decision based on their committees’ recommendations, the government’s budget for drug programs, and what is in the public interest. The Association actively seeks input on diabetes drugs under review, to ensure views from people with diabetes and their caregivers are taken into consideration in the drug review processes.

The patient input/evidence submissions are based on survey responses from people living with diabetes and their caregivers. The responses are analyzed, summarized and submitted to drug review bodies using standardized templates.

Please note: The Canadian Diabetes Association does not endorse nor recommend any particular drug for the management of type 2 diabetes. Across the country, we advocate for equitable and affordable access to diabetes drugs, devices and supplies to ensure people with diabetes have the support needed to effectively self-manage their condition.

If you have any questions about the information above, please contact the Canadian Diabetes Association at 613-688-5941 or advocacy@diabetes.ca.


CADTH: Therapeutic Review

Common Drug Review


British Columbia